Case Series
The Clinical Impact of Vascular Endothelial Growth Factor/Receptor (VEGF/R) Inhibitors on Voice
Table 1
Laryngeal findings following VEGF/R inhibitor therapy.
| | | G | Age | Diagnosis | Primary chemotherapy | VEGFI | Duration of therapy | Time to onset of dysphonia | Laryngeal findings | MPT (s) | Treatment for dysphonia | Duration of dysphonia | Follow-up | Outcome |
| | 1 | F | 45 | Lung adeno-carcinoma | Erlotinib | Bevacizumab | 10 months | 2 days | BVF bowing | 5 | Speech therapy | 10 months | 10 months | Persistent bowing and dysphonia | | 2 | F | 52 | Breast adeno-carcinoma | Capecitabine, paclitaxol | Bevacizumab | 3 months | 3 days | BVF bowing | 5 | Speech therapy | 6 months | 8 months | Normal vocal folds | | 3 | M | 64 | Colon adeno-carcinoma | Cisplatin, pemetrexed | Aflibercept | 3 months | 7 days | BVF bowing | 4 | Speech therapy | 4 months | 12 months | Normal vocal folds | | 4 | F | 65 | Lung adeno-carcinoma | Carboplatin, pemetrexed disodium | Bevacizumab | 8 months | 3 days | BVF bowing | 6 | Observation | 8 months | 9 months | Persistent bowing and dysphonia |
|
|
BVF: bilateral vocal fold, VEGFI: vascular endothelial growth factor inhibitor.
|
